[ad_1]
Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? BJU Int. 2021;127:389–99. https://doi.org/10.1111/bju.15229
Google Scholar
Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1:1–6.
Google Scholar
Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161:1174–9.
Google Scholar
Madersbacher S, Haidinger G, Temml C, Schmidbauer CP. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol. 1998;34:136–41. https://doi.org/10.1159/000019699
Google Scholar
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin N Am. 2016;43:289–97. https://doi.org/10.1016/j.ucl.2016.04.001
Google Scholar
Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65:458–64. https://doi.org/10.1159/000496289
Google Scholar
Choi WS, Son H. The change of IPSS 7 (nocturia) score has the maximum influence on the change of Qol score in patients with lower urinary tract symptoms. World J Urol. 2019;37:719–25. https://doi.org/10.1007/s00345-018-2410-8
Google Scholar
Albisinni S, Aoun F, Roumeguère T, Porpiglia F, Tubaro A, DE Nunzio C. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nefrol. 2017;69:119–32. https://doi.org/10.23736/S0393-2249.16.02743-0
Google Scholar
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. https://doi.org/10.1016/s0022-5347(17)36966-5.
Google Scholar
Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J. International Scientific Committee. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181:1779–87. https://doi.org/10.1016/j.juro.2008.11.127
Google Scholar
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995;33:AS145–55.
Google Scholar
Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postgrad Med. 2015;127:301–7. https://doi.org/10.1080/00325481.2015.1018799
Google Scholar
O’Leary MP, Wei JT, Roehrborn CG, Miner M, BPH Registry and Patient Survey Steering Committee. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int. 2008;101:1531–5. https://doi.org/10.1111/j.1464-410X.2008.07574.x
Google Scholar
Kingery L, Martin ML, Naegeli AN, Khan S, Viktrup L. Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. Int J Clin Pract. 2012;66:883–90. https://doi.org/10.1111/j.1742-1241.2012.02960.x
Google Scholar
Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, et al. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69:1091–101. https://doi.org/10.1016/j.eururo.2015.12.034
Google Scholar
Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary KT, et al. Tadalafil alone or in combination with tamsulosin for the management for LUTS/BPH and ED. Curr Urol Rep. 2020;21:56 https://doi.org/10.1007/s11934-020-01009-7
Google Scholar
Hong SK, Min GE, Ha SB, Doo SH, Kang MY, Park HJ, et al. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int. 2010;105:970–4. https://doi.org/10.1111/j.1464-410X.2009.08915.x
Google Scholar
Joo K-J, Sung W-S, Park S-H, Yang W-J, Kim T-H. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res. 2012;40:899–908. https://doi.org/10.1177/147323001204000308
Google Scholar
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31. https://doi.org/10.1016/j.eururo.2009.09.035
Google Scholar
Roehrborn CG, Perez IO, Roos EPM, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®)) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116:450–9. https://doi.org/10.1111/bju.13033
Google Scholar
Choi JD, Kim JH, Ahn SH. Transitional zone index as a predictor of the efficacy of α-blocker and 5α-reductase inhibitor combination therapy in Korean patients with benign prostatic hyperplasia. Urol Int. 2016;96:406–12. https://doi.org/10.1159/000442995
Google Scholar
Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol. 2021;13. https://doi.org/10.1177/1756287221993283
Jiang Y-L, Qian L-J. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. 2019;19:11 https://doi.org/10.1186/s12894-019-0440-1
Google Scholar
Liu Y, Cheng Y, Zhuo L, Liu K, Xiao C, Zhao R, et al. Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Endourol. 2020;34:1064–74. https://doi.org/10.1089/end.2020.0141
Google Scholar
Tanneru K, Jazayeri SB, Alam MU, Kumar J, Bazargani S, Kuntz G, et al. An indirect comparison of newer minimally invasive treatments for benign prostatic hyperplasia: a network meta-analysis model. J Endourol. 2021;35:409–16. https://doi.org/10.1089/end.2020.0739
Google Scholar
Abt D, Hechelhammer L, Müllhaupt G, Markart S, Güsewell S, Kessler TM, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338 https://doi.org/10.1136/bmj.k2338
Google Scholar
Spatafora S, Canepa G, Migliari R, Rotondo S, Mandressi A, Puppo P. Diagnostic procedures by Italian general practitioners in response to lower urinary tract symptoms in male patients: a prospective study. Curr Med Res Opin. 2004;20:713–21. https://doi.org/10.1185/030079904125003557
Google Scholar
McNicholas TA. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the current practice patterns? Eur Urol. 2001;39 Suppl 3:26–30. https://doi.org/10.1159/000052564
Google Scholar
Spatafora S, Canepa G, Migliari R, Rotondo S, Mandressi A, Puppo P, et al. Effects of a shared protocol between urologists and general practitioners on referral patterns and initial diagnostic management of men with lower urinary tract symptoms in Italy: the Prostate Destination study. BJU Int. 2005;95:563–70. https://doi.org/10.1111/j.1464-410X.2005.05340.x
Google Scholar
Li J, Peng L, Cao D, Gou H, Li Y, Wei O. The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis. Aging Male. 2020;23:1388–99. https://doi.org/10.1080/13685538.2020.1771552
Google Scholar
Xia B-W, Zhao S, Chen Z, Chen C, Liu T, Yang F, et al. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. Prostate. 2020;80:481–90. https://doi.org/10.1002/pros.23962
Google Scholar
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432–41. https://doi.org/10.1111/bju.12118
Google Scholar
Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, Capitanio U, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011;52:507–16. https://doi.org/10.4111/kju.2011.52.8.507
Google Scholar
Wang X, Su Y, Yang C, Hu Y, Dong J-Y. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men. World J Urol. 2021. https://doi.org/10.1007/s00345-021-03817-z.
Google Scholar
Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108–19. https://doi.org/10.1038/nrurol.2015.301
Google Scholar
Ngai H-Y, Yuen K-KS, Ng C-M, Cheng C-H, Chu S-KP. Metabolic syndrome and benign prostatic hyperplasia: an update. Asian J Urol. 2017;4:164–73. https://doi.org/10.1016/j.ajur.2017.05.001
Google Scholar
De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13:613–26. https://doi.org/10.1038/nrurol.2016.168
Google Scholar
Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care. 2008;31:476–82. https://doi.org/10.2337/dc07-1148
Google Scholar
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015;67:1066–96. https://doi.org/10.1016/j.eururo.2014.06.017
Google Scholar
Cindolo L, Pirozzi L, Sountoulides P, Fanizza C, Romero M, Castellan P, et al. Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15:96. https://doi.org/10.1186/s12894-015-0090-x
Google Scholar
[ad_2]
Source link
